MaxCyte is a global life sciences company applying proprietary cell engineering technology to deliver the advances of cell-based medicine to patients. All top 10 global biopharmaceutical companies are developing next-generation therapeutics utilizing MaxCyte's Flow Electroporation® Technology. MaxCyte's 70+ partnered program licenses in cell therapy include 35+ licensed for clinical use.